Background {#Sec1}
==========

Dabigatran is a novel synthetic, nonpeptidic, potent, specific, competitive, and reversible inhibitor of thrombin. Its marketed form is the prodrug dabigatran etexilate, which has been approved for the primary prevention of venous thromboembolism after total elective hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) in numerous countries. Further indications are under evaluation \[[@CR1]\].

Dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalyzed hydrolysis \[[@CR2]\]. Maximum plasma concentrations of dabigatran occur approximately 2--3 h after oral dosing. The disposition is biexponential, the terminal half-life is 12--17 h \[[@CR3], [@CR4]\], and steady state is attained after about 3 days of twice-daily treatment \[[@CR5]\]. The total and peak systemic exposure are dose-proportional over the whole investigated range from 50 mg up to 400 mg \[[@CR3]\]. Two food interaction studies showed that total areas under the plasma concentration--time curve (AUC) and peak plasma concentrations (*C*~max~) remained essentially unchanged under fasted and fed conditions. Food delayed the time to the *C*~max~ (*t*~max~) of dabigatran by about 2 h \[[@CR6]\].

The oral bioavailability of dabigatran etexilate in capsules is about 6.5 % \[[@CR3]\]. Dabigatran is eliminated mainly (85 % of the dose) via renal glomerular filtration \[[@CR2], [@CR7]--[@CR10]\], whereby 80 % is excreted unchanged and 20 % is eliminated as glucuronide. A protein binding study with radiolabeled dabigatran showed that 35 % of the dabigatran is bound to plasma proteins over a wide concentration range \[[@CR2]\]. The prodrug dabigatran etexilate---but not the active moiety dabigatran---is a substrate of P-glycoprotein (P-gp) \[[@CR11]\].

Certain situations such as the need for emergency surgery in patients on anticoagulant medications may require rapid reversal of their anticoagulant effects. Hemodialysis has been shown to be one method that can reverse the anticoagulant effects of dabigatran by removing it from the blood \[[@CR10], [@CR12]--[@CR14]\]. However, no investigation of various clinically relevant dialysis settings (such as filter properties or flow rates) aimed at a better understanding of the elimination of dabigatran has been carried out. One prior study was conducted in a subgroup of a phase I study, wherein six volunteers with end-stage renal disease (ESRD) were dialyzed after administration of 50 mg dabigatran etexilate. It was shown that a substantial fraction of the dabigatran was eliminated by hemodialysis \[[@CR10]\]. To further increase knowledge about dialyzing dabigatran, a dedicated phase I study was conducted in seven additional ESRD patients \[[@CR12]\]. The study was designed using simulation methodology, with a focus on the maximization of potential redistribution effects \[[@CR15]\]. The study demonstrated that a 4-h hemodialysis eliminated 49--59 % of dabigatran from circulation \[[@CR12]\].

The objectives of the work presented here were firstly to characterize the effects of hemodialysis at different blood flow rates on the pharmacokinetics of dabigatran by pharmacometric approaches using data from a dedicated phase I dialysis study \[[@CR12]\]. The final model was evaluated through the prediction of external data \[[@CR14]\]. Secondly, the effects of various clinically relevant hemodialysis conditions on dabigatran elimination were evaluated via simulations to assess their potential use in non-ESRD situations.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The data from a phase I dialysis study performed by Khadzhynov and colleagues \[[@CR12]\] served as the basis for our analysis. A detailed description of the study design and results was published previously \[[@CR12]\]. In brief, the primary objectives of the study were the evaluation of blood and plasma dialysis clearance and the proportion of dabigatran removed from the central compartment during a standardized 4-h hemodialysis session. Secondary objectives were to evaluate pharmacokinetic measures, pharmacodynamics \[activated partial thromboplastin time (aPTT) and the diluted thrombin time (dTT)\], and safety parameters.

The study was designed as a nonrandomized, open-label, two-period, fixed-sequence, multiple-dose study with two standard hemodialysis elimination settings (see below). A washout phase of ≥6 weeks between periods was included. Seven dialysis-dependent ESRD subjects without atrial fibrillation were entered into and completed the trial. For both trial periods, three dabigatran etexilate doses were administered, each separated by a period of 21 h: one dose of 150 mg dabigatran etexilate shortly after hemodialysis on day 1; one dose of 110 mg dabigatran etexilate on day 2; and one dose of 75 mg dabigatran etexilate 8 h before hemodialysis on day 3. Hemodialysis 4 h in duration was performed on days 1, 3, and 5. The dialysis on day 1 was a standard dialysis without dabigatran exposure. On day 3, experimental dialysis was performed with different target blood flow rates of 200 mL/min and 400 mL/min in the first and second periods, respectively. The dialysis on day 5 was a slightly modified standard dialysis with a blood flow rate of 300 mL/min in both periods. The dialysate flow rate was 700 mL/min during all dialysis periods. A large-surface-area, high-flux filter (Polyflux PF-210H dialyzer, Gambro Dialysatoren GmbH, Hechingen, Germany) was used. To allow subsequent comparisons with the results from various simulation scenarios, the dialysis settings from period 1 (blood flow rate of 200 mL/min) were used as reference data.

Dabigatran plasma concentrations were measured at the following planned time points in relation to the first dose of dabigatran etexilate in all subjects: −4, 0 (day 1, pre-dose samples), 21, 22, 23, 25, 27, 33 (day 2), 42, 43, 44, 46, 48, 50, 51, 52, 53, 54, 58 (day 3), 62, 70, 82 (day 4), 91, 95 (day 5) h. The hemodialysis times in relation to the first dose of dabigatran etexilate were −4 to 0 h on day 1, 50 to 54 h on day 3, and 91 to 95 h on day 5. The study design, including the timing of samples in relation to the dabigatran dose administration and dialysis, is summarized in Fig. [1](#Fig1){ref-type="fig"}. Time of food intake in relation to administration varied from 17 to 90 min on the third day (fasted). Food intake time on day two was around 2 h before administration (fed).Fig. 1Schematic representation of the study design for a single period. *PK* pharmacokinetic

To measure free and conjugated dabigatran, blood samples were drawn into EDTA-containing tubes and immediately placed in an ice/water bath (0--4 °C) until centrifugation (at about 3,000×*g* for 10 min at 4 °C) for plasma preparation. Plasma samples were stored at −70 °C until analysis. The concentrations of nonconjugated, free dabigatran and total dabigatran (sum of free dabigatran + dabigatran glucuronide) in plasma were analyzed by high-performance liquid chromatography tandem mass spectrometry methods at Nuvisan GmbH (Neu-Ulm, Germany), as described elsewhere \[[@CR10]\]. Accuracy ranged from −4.9 to −2.6 % for total dabigatran concentrations of 3.00--320 ng/mL. Precision for the same range was between 3.8 and 4.5 %. The lower limit of quantification was 1.00 ng/mL. The method was validated according to the current Food and Drug Administration guidance on bioanalytical method validation \[[@CR16]\].

Data Analysis {#Sec4}
-------------

All modeling and simulation analyses were performed using the NONMEM^®^ software package (version VI 2.0; ICON Development Solutions, Ellicott City, MD, USA) or Berkeley Madonna (version 8.0.4; Berkeley Madonna Inc., University of California, Berkeley, CA, USA). Model selection was based on several criteria, such as goodness-of-fit plots, precision of model parameter estimates, and changes in the NONMEM^®^ objective function −2 log likelihood. When models were classified as nested, one model was declared superior to the other model when the objective function value was reduced by 3.84 (*P* \< 0.05, 1 *df*). The first-order conditional estimation with interaction method was used throughout model development. SAS (version 9.2; SAS Institute Inc., Cary, NC, USA) was used for statistical analyses. Graphics were generated using SigmaPlot (version 10.0; Systat Software, Inc., Richmond, CA, USA) or Visio (Version 2007; Microsoft Corporation, Redmond, WA, USA).

The pharmacokinetic model that was developed to optimize the study design of the hemodialysis study served as a starting point for the data analysis \[[@CR15]\]. The model consisted of two disposition compartments with first-order absorption and a lag time. An apparent dabigatran dialysis clearance (CL~dialysis~/*F*) was implemented in addition to the intrinsic total body clearance (CL/*F*) in ESRD subjects (renal and nonrenal elimination). The dialysis clearance was greater than zero during the hemodialysis and zero during the interdialytic periods. The total apparent dabigatran clearance (CL~total~/*F*) is the sum of CL/*F* and CL~dialysis~/*F.* The apparent dialysis clearances in L/h were converted to actual dialysis clearances in mL/min, assuming a typical bioavailability of 6 %.

Initially, for each investigated blood flow rate, a separate apparent dabigatran dialysis clearance was estimated. In a second step, the relationship between blood flow rate and apparent dabigatran dialysis clearance was explored using various functions, such as a linear model, a maximum effect (*E*~max~) model, and the Michaels equation (Eq. [1](#Equ1){ref-type=""}) \[[@CR17]\]:$$\documentclass[12pt]{minimal}
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Several statistical models to describe variability were evaluated. Residual variability was described by a proportional model. Interindividual variability (IIV) and interoccasion variability (IOV) were modeled using exponential random effect models. The following definitions of "occasion" were tested: (a) study period and (b) dosing interval.

The maximum redistribution in percent (Redist~max~) was calculated according to Eq. [2](#Equ2){ref-type=""}:$$\documentclass[12pt]{minimal}
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Simulations {#Sec5}
-----------

Three different clinical scenarios were simulated. Scenario 1 evaluated the effect of variations in dialysis settings on the reduction in plasma concentration. Simulated patients were given oral dabigatran and dialyzed as defined in the study protocol during period 1 \[[@CR12]\]. Variations in the hemodialysis filter with respect to the manufacturer (Fresenius instead of Gambro), the effective membrane surface (reduced by 20 %), the membrane type (low-flux instead of high-flux membrane), and the membrane material (Poracton instead of Polyamix) were mimicked by varying the dialysis clearance by −5, −10, −20, and +10 %, respectively. A reduced dialysate flow rate of 500 mL/min instead of 700 mL/min was calculated to reduce CL~dialysis~ by 5 %. Also, blood flow rates of 150, 250, and 400 mL/min were simulated. In addition, a worst case scenario was investigated where several effects were added simultaneously, resulting in a reduction in the dialysis clearance of 40 %.

Scenario 2 systematically explored the maximum redistribution effect. Scenario 3 studied the effect of variations in the renal function and the duration of dialysis on the reduction in plasma concentration. In both scenarios, simulated AF patients were dosed with 150 mg twice daily to steady state. Dialysis was started 12 h after the last dose. The duration of dialysis was varied from 1 to 10 h. Creatinine clearance (CL~CR~) values of 30, 50, 70, and 100 mL/min were simulated.

To mimic AF patients, all simulations were performed utilizing pharmacokinetic parameter estimates from the RE-LY trial \[[@CR9]\]. Demographic and other covariates were set to a typical patient from the RE-LY trial (Caucasian male, 72 years old, body weight of 80.3 kg, hemoglobin 14.3 mg/dL, no comedications). Only median profiles were simulated.

Model Evaluation {#Sec6}
----------------

The population pharmacokinetic model was evaluated by predicting the plasma concentration time course of an external data set from a patient undergoing hemodialysis from a literature report \[[@CR14]\]. The structural dialysis model developed in this report was applied. The pharmacokinetic absorption and distribution parameters from a typical AF patient in the RE-LY trial \[[@CR9]\] were used. The total body clearance was set to 10 L/h. The apparent dialysis clearance was calculated to be 180.3 L/h, based on the reported average blood flow rate of 320 mL/min. The dialysis duration was 6 h, as reported. Interindividual variability in bioavailability (*F*) was set to zero. An additional interindividual variability of 15 % was introduced for the blood flow rate, as this was reported to vary \[[@CR14]\]. Interindividual variability of 10 % in the mass transfer-area coefficient (*K*~o~*A*) was introduced to reflect the uncertainty in its value. The residual variability from the RE-LY trial was applied. An appropriate dose was developed to reach the reported plasma concentration of 76 ng/mL at the start of hemodialysis 48 h after the last dosing. The same filter and dialysis flow rate were applied in the present study as used in the case reported \[[@CR14]\]. The plasma concentration time profile of the patient was simulated 5,000 times and the corresponding median and 5th and 95th percentiles were calculated. To evaluate the predictive performance, the predicted profile was overlaid with the reported concentrations of the patient from the publication \[[@CR14]\].

Results {#Sec7}
=======

Population Pharmacokinetic Model {#Sec8}
--------------------------------

All 7 ESRD subjects enrolled in this study were white males with a mean age of 38.3 years (range 27--53 years) and a mean body weight of 74.0 kg (range 60--87 kg). The dataset consisted of 308 observations (total dabigatran plasma concentrations) and 42 dose administration records. All data records were included in the analysis. The geometric means of the trough plasma concentrations after the second dose were 140 ng/mL (coefficient of variation \[CV\] 54.2 %) and 128 ng/mL (CV 44.5 %) in periods 1 and 2, respectively.

The pharmacokinetics of dabigatran were best described using a two-compartment disposition model with first-order absorption. As the timing of food intake relative to dabigatran administration varied throughout the study, different lag times and an *E*~max~ function of the food intake time relative to dabigatran administration were incorporated into the model to account for this effect on the absorption.

The final pharmacokinetic model included two parallel first-order clearance pathways. First, an apparent total body dabigatran clearance (CL/*F*) was introduced. CL/*F* in ESRD subjects was estimated at 12.4 L/h. Variations in the serum creatinine levels did not explain any variation in the total body drug clearance. Second, an apparent dialysis clearance (CL~dialysis~/*F*) was implemented in parallel to describe the accelerated drug clearance caused by hemodialysis. The dialysis clearance was greater than zero during the hemodialysis periods and zero during the interdialytic periods. The effect of blood flow rate on the dialysis clearance was best described using the Michaels equation \[[@CR17]\]; the objective function decreased significantly by 22.354 points compared to the model with constant dialysis clearance.

*K*~o~*A* was estimated at 313 mL/min. Figure [2](#Fig2){ref-type="fig"} depicts the schematic pharmacokinetic model and the relationship between blood flow rate and dialysis clearance. The total apparent dabigatran clearance (CL~total~/*F*) is the sum of CL/*F* and CL~dialysis~/*F*. Model-derived values of the different apparent clearance parameters for the investigated blood flow rates are shown in Table [1](#Tab1){ref-type="table"}.Fig. 2**a** Schematic illustration of the final pharmacokinetic model. **b** Relationship between blood flow rate and apparent dialysis clearance of dabigatran for a dialysate flow rate of 700 mL/min and an estimated mass transfer-area coefficient of 313 mL/minTable 1Apparent total body clearance during the interdialytic period (CL/*F*), apparent dialysis clearance (CL~dialysis~/*F*), and apparent total clearance (CL~total~/*F*), as derived from the parameters of the final population pharmacokinetic modelBlood flow rate (mL/min)Apparent clearance parametersCL/*F* (L/h)CL~dialysis~/*F* (L/h)CL~total~/*F* (L/h)20012.4148.5160.930012.4176.4188.840012.4192.7205.1

Interindividual variability was implemented in CL/*F* and the apparent volume distribution of the central compartment (V~2~/*F*). Interoccasion variability was implemented in *F* and the first-order absorption rate constant (*k*~a~), where one occasion was defined for each dosing interval. The residual variability was described by a proportional residual variability model. All parameters of the final model were estimated with good precision (relative standard errors ranging from 4.6 to 48.5 %, Table [2](#Tab2){ref-type="table"}). The goodness-of-fit plots of the final model are shown in Fig. [3](#Fig3){ref-type="fig"}. All observed versus predicted concentrations were in general spread randomly around the line of identity, indicating that the data were well described by the model; no trend over time was observable. The epsilon shrinkage was 10.4 %.Table 2Parameter estimates from the final population pharmacokinetic modelParameterValueRSE (%)DescriptionFixed effects CL/*F*^a^ (L/h)12.428.71Total body clearance (renal and nonrenal) *V*~2~/*F* (L)53122.60Volume of distribution of the central compartment *Q*/*F* (L/h)15214.34Intercompartmental clearance *V*~3~/*F* (L)4999.42Volume of distribution of the peripheral compartment *k*~a~ (h^−1^)0.82116.81First-order absorption rate constant ALAG (h)1.674.56Absorption lag time ALAG~\_3rd~ (h)0^b^--Absorption lag time of the third dose (fasted) *F*1.00^b^--Relative bioavailability EC~50\ food\ time~^c^ (h)0.55611.13Time between dose administration and food intake at which the effect on bioavailability is half of the maximum effect *F*~min\ food\ time~^c^0^b^--Minimum bioavailability when time between dose administration and food intake is 0 (fixed to 0 due to limited data) Hill~food\ time~^c^6.1048.52Hill factor describing the steepness of the relation between time to food intake and the relative bioavailability *K*~o~*A*^d^ (mL/min)31323.39Hemodialyzer mass transfer-area coefficientRandom effects: interindividual variability (IIV) and interoccasion variability (IOV) IIV CL/*F* (CV%)40.443.01IIV in the total body clearance IIV *V*~2~/*F* (CV%)14.343.07IIV in the apparent volume of distribution of the central compartment IOV *k*~a~ (CV%)64.030.24IOV in the relative first-order absorption rate constant IOV *F* (CV%)48.026.91IOV in the relative bioavailabilityRandom effects: residual variability PRV (CV%)8.524.00Proportional residual variability^a^CL~total~/*F* = CL~dialysis~/*F* + θ~CL/*F*~ × e^ηCLb^Parameters fixed^c^F~3rd_dose~ = (θ~Fmin\ food\ time~ + (1 − θ~Fmin\ food\ time~) × $\documentclass[12pt]{minimal}
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Simulations {#Sec9}
-----------

The effects of varying the dialysis settings are shown in Fig. [4](#Fig4){ref-type="fig"}. Compared to the reference, the effects of individual factors on the reduction in plasma concentration were rather small (−7 to +8 %). Even in a worst case scenario where the effects accumulated, only a limited decrease in plasma concentration of 14 % compared to the reference was predicted.Fig. 4Simulated percentage changes in dialysis clearance and the resulting changes in reduction in plasma concentration for various dialysis settings compared to the reference. Reference settings were: blood flow rate (BFR) = 200 mL/min, dialysate flow rate (DFR) = 700 mL/min, filter = large surface, high flux (Gambro PF-210H). For details, see "[Methods](#Sec2){ref-type="sec"}"

Simulation scenario 2 systematically investigated the maximum redistribution effect. Simulations predicted a maximum redistribution effect in AF patients with a low creatinine clearance of 30 mL/min after a 10-h dialysis (Fig. [5](#Fig5){ref-type="fig"}). The maximum typical redistribution was 26 %, which corresponds to an increase in dabigatran plasma concentration of 8.5 ng/mL. After shorter dialysis duration of 4 h, the typical redistribution would be even smaller, with an increase of 1.2 ng/mL.Fig. 5Simulated time profile of plasma concentration for the maximum redistribution effect observed after a 10-h dialysis in a patient with a creatinine clearance of 30 mL/min (*solid line*) and without dialysis (*dotted line*)

The effects of dialysis duration and total body clearance on the relative reduction in plasma concentration are shown in Fig. [6](#Fig6){ref-type="fig"}a. The impact of dialysis duration on the absolute reduction in dabigatran plasma concentration is shown in Fig. [6](#Fig6){ref-type="fig"}b. Three different starting concentrations are shown as examples, reflecting the observed 50th, 90th, and 99.6th percentiles of the trough plasma concentration of the 150 mg dose group in the RE-LY trial \[[@CR18]\]. A substantial reduction in plasma concentration was predicted that was also dependent on the dialysis duration. The effect of the total body clearance on the reduction in plasma concentration was rather small over the time range investigated (\<7 % difference). The impact on the reduction in the plasma concentration was strong during the first few hours, but the response curves became shallower the longer the dialysis continued.Fig. 6**a** Predicted reduction in plasma concentration (%) vs. duration of dialysis displayed for patients with different creatinine clearance values. **b** Predicted plasma concentrations vs. duration of dialysis for three different initial concentrations representing the observed median and the 90th and 99.6th percentiles of the trough plasma concentrations of the 150 mg dose group in the RE-LY trial. *CL*~*CR*~ creatinine clearance

Model Evaluation {#Sec10}
----------------

The final population pharmacokinetic model was externally evaluated through the prediction of the time profile of the plasma concentrations measured in a patient undergoing hemodialysis \[[@CR14]\]. The predictions showed good agreement with the measured values; all observed concentrations were within the 90 % prediction interval (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7External prediction of the time profile of the plasma concentrations measured in a patient undergoing hemodialysis. Measured values are shown as *open circles*. Predicted median and 5th and 95th percentiles are represented as *lines*

Discussion {#Sec11}
==========

A population pharmacokinetic model was successfully developed for ESRD subjects to characterize the effects of hemodialysis at different blood flow rates on the plasma concentrations of dabigatran. The highly variable absorption process was clearly separated from the hemodialysis process. This allowed precise estimates to be obtained for the hemodialysis parameters and an acceptable description of the redistribution process.

In this ESRD population, a low total body dabigatran clearance of 12.4 L/h was estimated. Considering the negligible renal clearance of dabigatran in this population (\<0.04 L/h) \[[@CR12]\], it can be concluded that the estimated total body clearance mainly covers nonrenal excretion. In the RE-LY study, a total dabigatran clearance of 69.6 L/h was reported for typical AF patients \[[@CR9]\]. This total clearance is a composite of renal and nonrenal elimination pathways. Assuming that the nonrenal clearance component calculated from the present analysis is applicable, then the contribution of the renal elimination to the total clearance for typical AF patients is 82 %. This agrees well with results from a healthy volunteers in a phase I study in which about 85 % of the dabigatran dose was eliminated renally in non-ESRD subjects \[[@CR2]\]. The absorption and distribution processes of dabigatran in ESRD patients were comparable to those in healthy subjects \[[@CR7]\]. The 21-h dosing interval during the study caused variations in food intake on days 2 and 3 in relation to dabigatran administration. To account for this difference, different lag times and an *E*~max~ function were included in the model. The effect observed on *t*~max~ was absolutely identical to that noted in a report in the literature \[[@CR6]\]. Even though the food effect was statistically significant, the described effect needs to be interpreted with caution due to the specific population, the specific study design and the small sample size.

The relationship between the blood flow rate, the dialysis flow rate and the dialysis clearance was best described by the well-established Michaels model \[[@CR17]\]. This is not surprising, as the equation was specifically developed to quantify dialysis and has been frequently applied \[[@CR19]\]. The equation provides great flexibility in predicting the effects of variations in the dialysis flow rate and the blood flow rate. Applied to the present data, it clearly demonstrates the limitations of increased flow rates, since doubling the blood flow rate from 200 to 400 mL/min increases the dialysis clearance by only 30 % and results in an additional reduction of the dabigatran concentration by only about 8 %. The Michaels model assumes a constant mass transfer-area coefficient. This coefficient is a property of the solute and the dialyzer. *K*~o~*A* is expected to be independent of solute concentrations and flow rates. Even though some publications report different findings \[[@CR20]--[@CR22]\], the differences in *K*~o~*A* reported were small, so the assumption seems acceptable. The simulations demonstrated the flexibility and usefulness of the applied Michaels model, since changes in the blood flow rate and dialysate flow rate can be directly translated into changes in CL~dialysis~/*F*.

Overall, no interindividual variability was identified in the dialysis clearance. This finding is in agreement with the low variability observed in the extraction ratio (\<10 % geometric coefficient of variation) in the previous phase I study \[[@CR12]\].

Overall, the simulations revealed that variations in dialysis settings have only a limited effect on the reduction in plasma concentration, whereas the dialysis duration is a key factor in the reduction process. Due to the first-order elimination process, the reduction in the plasma concentration is initially large, but it becomes smaller with increasing dialysis duration.

As redistribution of dabigatran after the end of the hemodialysis may result in a clinically relevant increase in plasma concentration, the study design was optimized for a maximum redistribution effect \[[@CR15]\]. In general, the extent of redistribution depends on several factors, such as the amount of drug available in peripheral compartments for redistribution, the intercompartmental clearance, the intrinsic clearance, and the hemodialysis clearance. The simulations for dabigatran showed that the average redistribution effect after dialysis is probably low. This finding is in agreement with the observed study results, which showed a small geometric mean redistribution of ≤15.5 % \[[@CR12]\].

The effect of renal function on the elimination of dabigatran is well characterized and expected for a drug that is mainly eliminated via the kidney \[[@CR10]\]. In previous analyses, the relationship between CL~CR~ and dabigatran clearance was described by a hockey-stick or an *E*~max~ model \[[@CR7], [@CR9]\]. In the analysis presented here, no relationship could be established between dabigatran clearance and the serum creatinine or CL~CR~ measurements of the ESRD subjects. This is not surprising, as renal elimination in ESRD patients does not play any role \[[@CR12]\].

Even though the renal function plays a major role in the excretion of dabigatran in non-ESRD patients, simulations predicted that the renal status of the dialyzed patient may be of minor importance with respect to the reduction in the plasma concentration and the redistribution effect (Fig. [6](#Fig6){ref-type="fig"}a). This is not surprising, since CL~dialysis~/*F* is approximately 2- to 3-fold higher than the body clearance of an AF patient with median renal function, and therefore represents the major elimination pathway during the dialysis.

The final model was evaluated through the prediction of measured plasma concentrations from a case report of a dabigatran-treated patient undergoing dialysis \[[@CR14]\]. The almost negligible decline in the terminal phase confirms the assumed low total body clearance of this patient. The observed profile was well within the 90 % prediction interval and underlines the predictive performance of the model. However, although this single case was predicted successfully, additional data would be required to fully validate the predictive performance of the model.

The early application of pharmacometric approaches during the design phase of the study contributed significantly to its success \[[@CR12]\]. The primary focus during the optimization of the study design was on the dosing scheme, the start time, and the duration of the dialysis. The aim was to reach comparable plasma concentrations to those in AF patients in order to be able to assess the redistribution effect in subjects with therapeutic dabigatran plasma concentrations and to allow precise estimation of the dialysis parameters. The developed dosage regimen of 150 mg, 110 mg, and 75 mg administered during the interdialytic period resulted in plasma concentrations in the range of the expected values (predicted *C*~max~: 154 ng/mL; observed *C*~max~: 176 ng/mL for period 1 and 159 ng/mL for period 2).

The analysis presented here has some limitations. First, the number of study subjects was relatively small (*n* = 7), with a total of 28 hemodialysis sessions. Nevertheless, all parameters were estimated precisely, and the absorption and distribution processes of dabigatran in ESRD patients were comparable to those in healthy subjects \[[@CR7]\]. Secondly, all study subjects were male Caucasians in the therapeutic concentration range. However, there is no evidence that the pharmacokinetics of dabigatran are significantly influenced by ethnicity or sex after adjustment for renal function \[[@CR7], [@CR9]\]. Furthermore, since the dialysis clearance is concentration independent and mainly influenced by certain physicochemical properties of the dialysis filter and the protein binding of the studied drug, it seems justified to expect that results would be similar in women, patients of other ethnicities, and importantly in patients with the target indication, AF. Also, similar results would theoretically be expected in patients with supratherapeutic plasma concentrations.

Conclusions {#Sec12}
===========

Overall, the effect of dialysis is a complex interplay of many factors, such as duration of dialysis, start of dialysis, blood flow rate, dosing history, patient demographics, and many others. This first thorough analysis of the effects of various dialysis factors on dabigatran pharmacokinetics may allow the effect of dialysis on the plasma concentration to be predicted under various conditions. Dialysis duration was identified as having the greatest impact on the extent of dabigatran plasma concentration reduction. The developed model can potentially serve as a tool to provide guidance when considering the use of hemodialysis in patients that have received dabigatran. Further data will be required to validate the predictive performance of the model.
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